Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A. Kharfan‐Dabaja(Jacksonville College), Bipin N. Savani(Vanderbilt University Medical Center), Ernesto Ayala(Mayo Clinic in Florida), Francesco d’Amore(Aarhus University), Mehdi Hamadani(Medical College of Wisconsin), Barbara Pro(The University of Texas MD Anderson Cancer Center), Paul A. Carpenter(Fred Hutch Cancer Center), Mohamad Mohty(Sorbonne Université), Ali Bazarbachi(American University of Beirut), Kensei Tobinai(National Cancer Center), Lubomir Sokol(Moffitt Cancer Center), Jonathan W. Friedberg(University of Rochester), Takashi Ishida(Keio University), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Hillard M. Lazarus(University Hospitals of Cleveland), Ranjana H. Advani(Stanford Medicine), Alison J. Moskowitz, Eric Tse(Queen Mary Hospital), Timothy S. Fenske(Medical College of Wisconsin), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Linda J. Burns(University of Minnesota System), Julio C. Chávez(Moffitt Cancer Center), Nishitha Reddy(Vanderbilt University), Michelle A. Fanale(Pfizer (United States)), Christian Gisselbrecht(Institut Universitaire de France), Francine M. Foss(Yale Cancer Center), Ambuj Kumar(University of South Florida), Peter Reimer(Essen University Hospital), Esa Jantunen(University of Eastern Finland), Ritsuro Suzuki(Nagoya University), Auayporn Nademanee(City Of Hope National Medical Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 154
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k